Blood BDNF level is gender specific in severe depression

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• Brain-derived neurotrophic factor (BDNF) is implicated in major depressive disorder (MDD) and antidepressant response.
• Its role in specific patient subgroups and as a diagnostic marker requires further clarification.

Purpose of the Study:

• To evaluate the diagnostic utility of serum BDNF levels for MDD severity and antidepressant efficacy.
• To investigate the relationship between BDNF, depression severity (HAM-D scores), and treatment response.

Main Methods:

• Serum BDNF levels were measured in 51 MDD patients and 38 controls at baseline and during an 8-week treatment period.
• Depression severity was assessed using the Hamilton Rating Scale for Depression (HAM-D).
• BDNF polymorphism (rs6265) was genotyped.

Main Results:

• A positive correlation between serum BDNF and depression severity was found only in untreated women with severe MDD (HAM-D>24).
• Untreated MDD patients exhibited lower serum BDNF levels compared to controls.
• Antidepressant treatment increased serum BDNF levels within two weeks.

Conclusions:

• BDNF is not a suitable universal biomarker for diagnosing MDD in the general population.
• Serum BDNF levels have diagnostic value for assessing disease progression and treatment efficacy in individual MDD patients.